Gary J. Schiller

Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein

Elizabeta Nemeth, Erika V. Valore, Mary Territo et al. · Blood · 2003 · 1.4K citations · Full text

Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study

Max S. Topp, Nicola Gökbuget, Anthony S. Stein et al. · The Lancet Oncology · 2014 · 1.2K citations

Hematological Malignancy, Lymphoid Neoplasia, Oncology +9

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia

Jeffrey E. Lancet, Geoffrey L. Uy, Jörge E. Cortes et al. · Journal of Clinical Oncology · 2018 · 958 citations · Full text

Mixed-phenotype Acute Leukemia, Pharmacotherapy, Metronomic Chemotherapy +16

KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study

Bijal Shah, Armin Ghobadi, Olalekan O. Oluwole et al. · The Lancet · 2021 · 721 citations · Full text

Hematological Malignancy, Lymphoid Neoplasia, Medicine +9

Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma

Ajai Chari, Dan T. Vogl, Maria Gavriatopoulou et al. · New England Journal of Medicine · 2019 · 655 citations · Full text